Ipamorelin dosage, as it appears in the studies — not as a protocol.

Read this first

This page reports ipamorelin dosage the way the studies report it — what was given, to which animal or which volunteers, by which route — and nothing more. There is no recommended human dose here, because none exists: ipamorelin is not an approved medicine, and the popular subcutaneous routines people use have never been tested for dose or safety in a published human study ^[15]. The numbers below are research figures. The human data come from just two studies — a pharmacokinetic study that mapped how the peptide clears ^[2] and a Phase 2 trial that used a fixed weight-based IV dose ^[3]. Everything else is from rats and other animals. The clearest fact a reader can take away is the timing: in people, ipamorelin clears with a half-life of about 2 hours and produces a single GH pulse roughly 40 minutes after a dose ^[2]. Treat the rest as 'this is what was studied,' never 'this is what to take.'

The doses actually studied

Across the published record, the doses administered were:

• Human PK/PD study: 4.21–140.45 nmol/kg IV over 15 minutes, as single doses, in healthy male volunteers ^[2].
• Human Phase 2 ileus RCT: 0.03 mg/kg IV twice daily for up to 7 days in bowel-resection patients ^[3].
• Rat bone-growth study: 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days ^[4].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneally ^[5].
• Rat glucocorticoid study: ipamorelin 0.4–1.6 mg/kg/day IV (four times daily), alongside methylprednisolone ^[14].

These are dosing facts from animal and early-human research, reported in third person. They are not a schedule for anyone.

Half-life, clearance, and the routes studied

In healthy human volunteers, ipamorelin's terminal half-life is approximately 2 hours (IV), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg; the GH response is a single discrete pulse peaking around 40 minutes (0.67 h) after dosing ^[2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6, with 60–80% of the dose recovered intact in bile and urine and intranasal bioavailability around 20% ^[12].

The routes that appear in the literature are intravenous (human PK and the clinical trial; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral absorption.

How much cjc-1295 ipamorelin should i take?

There is no answer to 'how much cjc-1295 ipamorelin should i take' that can be drawn from controlled human evidence, because no published human trial has dosed the combination for any outcome — the safe, accurate reply is that no validated human dose exists. The single-agent human data that does exist is a pharmacokinetic study using IV infusions of 4.21–140.45 nmol/kg ^[2] and a Phase 2 trial using 0.03 mg/kg IV ^[3]; neither establishes a self-administration dose, and community subcutaneous routines have no peer-reviewed basis. This site reports studied doses in third person and recommends none.

How to reconstitute cjc-1295 ipamorelin 5mg?

Questions about how to reconstitute cjc-1295 ipamorelin 5mg point to general peptide-handling, not a clinical procedure, and this site describes only what the research-supply literature notes. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general handling observations, not a preparation instruction, and there is no validated human-use protocol for the combination.

Why dosing precision is limited here

Human evidence for ipamorelin is limited and largely negative for the indication tested. One Phase 2 RCT (n=114) missed its primary endpoint ^[3]; one PK/PD study (n=8/dose) characterized the ~2-hour half-life ^[2]. There are no completed Phase 3 trials and no approved indication, so there is no labeled dose to quote. Most human use is off-label and self-administered without controlled-trial support, and a 2026 review explicitly flags the absence of validated efficacy-monitoring and safety frameworks for peptides in this class ^[15]. That gap is exactly why this page stays in the third person.